Recommended Topic Related To:

Perjeta

"The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-ap"...

Perjeta




PATIENT INFORMATION

  • Advise pregnant women and females of reproductive potential that PERJETA exposure can result in fetal harm, including embryo-fetal death or birth defects [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]
  • Advise females of reproductive potential to use effective contraception while receiving PERJETA and for 6 months following the last dose of PERJETA [see WARNINGS AND PRECAUTIONS and Use in Special Populations]
  • Advise nursing mothers treated with PERJETA to discontinue nursing or discontinue PERJETA, taking into account the importance of the drug to the mother [see Use in Specific Populations].
  • Encourage women who are exposed to PERJETA during pregnancy to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 [see WARNINGS AND PRECAUTIONS and Use in Specific Populations]

Last reviewed on RxList: 4/7/2015
This monograph has been modified to include the generic and brand name in many instances.

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Breast Cancer

Find support and advances in treatment.